Compare · GILD vs TWST
GILD vs TWST
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $162.43B, about 45.3x TWST ($3.58B).
- Over the past year, GILD is up 26.7% and TWST is up 54.9% - TWST leads by 28.1 points.
- GILD has been more active in the news (11 items in the past 4 weeks vs 8 for TWST).
- GILD has more recent analyst coverage (25 ratings vs 12 for TWST).
- Company
- Gilead Sciences Inc.
- Twist Bioscience Corporation
- Price
- $130.84+1.56%
- $58.38+2.91%
- Market cap
- $162.43B
- $3.58B
- 1M return
- -6.10%
- +22.78%
- 1Y return
- +26.74%
- +54.85%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2018
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 12
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest GILD
- Chairman & CEO O'Day Daniel Patrick sold $1,291,608 worth of shares (10,000 units at $129.16) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 632,567 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits, Other Events
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
- EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
Latest TWST
- Director Starovasnik Melissa A. sold $30,915 worth of shares (500 units at $61.83) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,222 units (SEC Form 4)
- President and COO Finn Patrick John sold $141,026 worth of shares (2,321 units at $60.76), decreasing direct ownership by 0.82% to 281,808 units (SEC Form 4) to cover withholding tax
- Chief Executive Officer Leproust Emily M. exercised 9,671 shares at a strike of $8.82 and sold $630,957 worth of shares (9,671 units at $65.24) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Laponis Adam
- Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
- SEC Form 4 filed by Laponis Adam
- SEC Form 4 filed by Laponis Adam
- SEC Form 144 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Starovasnik Melissa A.
- Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation